Clinical Trial

Efficacy of Oral Nigella Sativa as Adjuvant Therapy in Children With Moderate Persistent Asthma

Study acronym: Asthma
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated January 2, 2026 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Complementary and adjunctive therapies are increasingly being explored to enhance asthma control and reduce airway inflammation. Nigella sativa (black seed) is a medicinal plant used traditionally in multiple regions and has demonstrated anti-inflammatory, immunomodulatory, and bronchodilator effects. Its potential as an adjuvant therapy in asthma has attracted attention in both preclinical and clinical research
Trial Details
NCT Number NCT07315555
Lead Sponsor Tanta University
Conditions Community Acquired Pneumonia
Enrollment 90 participants
Start Date 2026-01-01
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-10-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-02